245% GAIN ON CANCER DETECTION COMPANY GH
ANOTHER 1000% GAIN POTENTIAL – BUYOUT TARGET
245% Gain
Guardant Health (GH) is long from $26.34. It is trading at $91.02 as of this writing, representing a 245% gain.
Buyout Target
GH is a buyout target.
Cancer Screening
Guardant Health is using advanced blood-based liquid biopsy tests and large clinical data sets to transform how cancer is detected, monitored, and treated.
The company’s core business includes its flagship Guardant360 liquid biopsy panel, Guardant Reveal for monitoring minimal residual disease, and early blood based cancer screening test Shield.
Potential Headwinds
Guardant Health is still working toward sustained profitability. It also faces competition from other diagnostics players and large pharma. Scaling depends on broader reimbursement and clinical adoption.
The Arora Report provides you investment opportunities to generate wealth from across the globe — now you can get a taste for free — free forever. Sign up below!
Earnings
GH stock jumped on strong earnings. Here are the details:
- Revenue came at $265.2M vs. $235.7M consensus.
- The company reported growth across the business.
- The company raised guidance for FY25 revenue to $965M – $970M from $915M – $925M.
Zones
GH is a volatile stock and trades in a wide range. Consider patiently waiting for a pullback.
For those following the Good Way, the Buy Now rating is *** (To see the locked content, please take a 30 day free trial).
For those following the Best Way, the buy zone is $*** – $***.
The maximum recommended quantity is ***% – ***%.
The mental stop zone is $*** – $***.
This is a very long term position. Consider continuing to hold without a target. The stock has the potential to ultimately go over $500.
What To Do Now
Those in GH may consider continuing to hold.
Those not in GH may consider following the parameters given above.
Profiting From Buyouts
Buyouts are a core wealth building strategy used by sophisticated investors such as billionaires and hedge funds. The Arora Report delivers this same approach to individual investors with notable success.
Recent Arora Portfolio buyouts include:
• Hologic (HOLX): 290% gain, acquired by Blackstone and TPG
• Akero Therapeutics (AKRO): Premium acquisition by Novo Nordisk for $60 per share,
• Electronic Arts (EA): 913% gain with a cash buyout offer of $210 per share
To date, 216 Arora Portfolio companies have been bought out, providing large gains for members who routinely invest in buyout targets. This performance is better than the firms that charge $50,000 per year and provide buyout advice. With The Arora Report, you get so much more.
Why This Matters Going Forward
The ongoing wave of consolidation points to increasing opportunity for buyouts in:
- Biotechnology and life sciences
- Artificial intelligence and data infrastructure
- Lithium and critical minerals
- Space, defense, and high-tech manufacturing
By being positioned early and following a disciplined process, investors may continue to benefit from upcoming M&A catalysts.
Start Your Free 30-Day Trial — Profit From the Next Buyout
New investors face uncertainty. Disciplined investors follow a proven framework. The Arora Report provides:
- Actionable signals in Real Time Feeds
- Buy zones that remove guesswork
- Strategies used by the most sophisticated investors
- Daily market guidance in the Morning Capsule
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
The Arora Report provides you investment opportunities to generate wealth from across the globe — now you can get a taste for free — free forever. Sign up below!